Susquehanna Fundamental Investments, LLC Autolus Therapeutics PLC Transaction History

Susquehanna Fundamental Investments, LLC

  • $4.33 Trillion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$2.04 - $3.76 $98,430 - $181,420
-48,250 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$3.52 - $5.46 $63,631 - $98,700
-18,077 Reduced 27.25%
48,250 $201,000
Q4 2021

Feb 14, 2022
SELL
$5.1 - $7.0 $169,947 - $233,261
-33,323 Reduced 33.44%
66,327 $344,000
Q3 2021

Nov 15, 2021
BUY
$5.32 - $7.37 $195,244 - $270,479
36,700 Added 58.3%
99,650 $653,000
Q2 2021

Aug 11, 2021
BUY
$4.78 - $7.96 $300,901 - $501,082
62,950 New
62,950 $418,000

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email